Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Sales | 46,230 | 39,148 | 56,949 | 60,232 | 25,556 |
| Cost of Goods | 22,333 | 1,877 | 4,649 | 5,622 | 626 |
| Gross Profit | 23,897 | 37,271 | 52,300 | 54,610 | 24,930 |
| Operating Expenses | 48,767 | 52,125 | 49,983 | 55,303 | 51,030 |
| Operating Income | -24,537 | -13,977 | 2,966 | -71 | -25,474 |
| Interest Expense | 2,078 | 2,613 | 3,205 | 3,755 | 4,286 |
| Other Income | 1,613 | 1,983 | 2,057 | 2,017 | 1,910 |
| Pre-tax Income | -25,002 | -14,607 | 1,818 | -1,809 | -27,850 |
| Income Tax | 13 | 17 | 22 | 317 | N/A |
| Net Income Continuous | -25,015 | -14,624 | 1,796 | -2,126 | -27,850 |
| Net Income | $-25,015 | $-14,624 | $1,796 | $-2,126 | $-27,850 |
| EPS Basic Total Ops | -0.17 | -0.10 | 0.01 | -0.02 | -0.19 |
| EPS Basic Continuous Ops | -0.17 | -0.10 | 0.01 | -0.01 | -0.19 |
| EPS Diluted Total Ops | -0.17 | -0.10 | 0.01 | -0.02 | -0.19 |
| EPS Diluted Continuous Ops | -0.17 | -0.10 | 0.01 | -0.01 | -0.19 |
| EBITDA(a) | $-23,798 | $-13,492 | $3,326 | $-71 | $-25,386 |